Effect of Fan Application in Preventing Ticagrelor-Associated Dyspnea

NCT07268859 | Recruiting DMC

• 2 other identifiers: ATADEK2024-10/449Is an identifier other
• Study Type: interventional
• Target: 110
• Locations: 1 country
• Sites: 2

Brief Summary

This study will be conducted in the coronary intensive care unit of Dr. Siyami Ersek Chest, Heart and Vascular Surgery Training and Research Hospital. It aims to investigate the effect of hand fan therapy on ticagrelor-associated dyspnea in patients receiving ticagrelor.

Conditions

Acute Coronary Syndromes; Ticagrelor; Dyspnea

Keywords

Nursing; Ticagrelor; Hand fan therapy; Dyspnea; Non-pharmacological intervention

Outcome Measures

Primary Outcomes (1)

• Incidence of ticagrelor-associated dyspnea

  The proportion of participants who experience dyspnea within 120 minutes following ticagrelor administration will be recorded.

  Time Frame: 0-120 minutes after ticagrelor administration (T1: baseline; T2: 30 min; T3: 60 min; T4: 120 min) Unit of Measure: Percentage of participants (%)

Secondary Outcomes (1)

• Time to onset of ticagrelor-associated dyspnea

  Time Frame: Within 120 minutes after ticagrelor administration (T1-T4) Unit of Measure: Minutes (min)

Other Outcomes (1)

• Severity of ticagrelor-associated dyspnea

  Time Frame: 0-120 minutes after ticagrelor administration (T1: baseline; T2: 30 min; T3: 60 min; T4: 120 min) Unit of Measure: Score (0-10)

Study Arms (2)

Standard Care (Control Group)

ACTIVE COMPARATOR

Routine ward care including semi-Fowler position and breathing exercises. Standard institutional care will be applied. Presence, number, and severity of dyspnea attacks will be recorded during the first 2 hours after ticagrelor administration.

Other: STANDART CARE

Standard Care + Fan Therapy (Experimental Group)

EXPERIMENTAL

In addition to standard care, patients will undergo hand fanning for 5 minutes at 30, 60, and 120 minutes after ticagrelor administration. The fan will be directed toward the patient's face from a distance of \~15 cm. Dyspnea severity and number of episodes will be recorded during this period. Device: Hand Fan

Other: STANDART CARE & FAN THERAPY

Interventions

STANDART CARE OTHER

Routine ward care including semi-Fowler position and breathing exercises. Standard institutional care will be applied. Presence, number, and severity of dyspnea attacks will be recorded during the first 2 hours after ticagrelor administration.

Standard Care (Control Group)

STANDART CARE & FAN THERAPY OTHER

In addition to standard care, patients will undergo hand fanning for 5 minutes at 30, 60, and 120 minutes after ticagrelor administration. The fan will be directed toward the patient's face from a distance of \~15 cm. Dyspnea severity and number of episodes will be recorded during this period.

Also known as: Fan

Standard Care + Fan Therapy (Experimental Group)

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Between the ages of 18 and 65,
• No severe hearing and vision problems,
• Can speak and understand Turkish,
• Easy to communicate with,
• First-time sufferer of acute coronary syndrome (ACS) for the first time,
• Decided to start ticagrelor therapy,
• Able to adapt to treatment,
• Individuals who volunteered to participate in the research.

You may not qualify if:

• Having any problem that prevents you from communicating cognitively, emotionally and verbally,
• Obstructive sleep abnormalities,
• Have a disease that affects respiratory function (stage IV cancer, bronchial asthma, COVID-19, lung cancer, pulmonary edema, chronic obstructive pulmonary disease, pulmonary hypertension, pulmonary embolism, pneumonia or bronchitis, etc.),
• With metabolic abnormalities,
• Intubated after the procedure,
• Previously treated with ticagrelor,
• Individuals who did not volunteer to participate in the study. Losses to follow up
• Individuals who wish to leave the study voluntarily.
• Saturation value below 95%,
• The one with the arrest,
• Who will not be able to fulfill the requirements of the work,
• Individuals with life-threatening conditions

Sponsors & Collaborators

• Acibadem University: lead

Study Sites (2)

İstanbul Üniversitesi-Cerrahapaşa

Istanbul, Avcılar, 34320, Turkey (Türkiye)

NOT YET RECRUITING

Sağlık Bilimleri Üniversitesi Dr. Siyami Ersek Göğüs Kalp ve Damar Cerrahisi Eğitim Araştırma Hastanesi

Istanbul, Üsküdar, 34668, Turkey (Türkiye)

RECRUITING

MeSH Terms

Conditions

Acute Coronary Syndrome; Dyspnea

Interventions

CCP110 protein, human

Condition Hierarchy (Ancestors)

Myocardial Ischemia; Heart Diseases; Cardiovascular Diseases; Vascular Diseases; Respiration Disorders; Respiratory Tract Diseases; Signs and Symptoms, Respiratory; Signs and Symptoms; Pathological Conditions, Signs and Symptoms

Central Study Contacts

Emine Tuğba YORULMAZ, research assistant

CONTACT

+905556177281; tugbayoorlmz@gmail.com

Arzu ERKOÇ, Associate professor

CONTACT

+905552735500; arzu.erkochut@iuc.edu.tr

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Masking Details: Outcomes will be assessed by a statistician not involved in the study. Participants and researchers will not be blinded due to the nature of the intervention.
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Model Details: Participants will be randomized into two groups: control and experimental. Randomization will be computer-based. Data will be analyzed by a statistician not involved in the study.

Study Record Dates

• First Submitted: June 18, 2025
• First Posted: December 8, 2025
• Study Start: March 15, 2025
• Primary Completion: January 10, 2026
• Study Completion: January 30, 2026
• Last Updated: December 8, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share

Locations

TU (2)